Anteris Technologies Global Corp (NASDAQ:AVR – Free Report) – Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Anteris Technologies Global in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn expects that the company will earn ($1.82) per share for the year. The consensus estimate for Anteris Technologies Global’s current full-year earnings is ($2.66) per share.
Anteris Technologies Global Price Performance
Shares of NASDAQ AVR opened at $4.87 on Wednesday. Anteris Technologies Global has a twelve month low of $2.34 and a twelve month high of $8.79. The firm has a 50-day simple moving average of $4.09.
Institutional Trading of Anteris Technologies Global
A number of hedge funds have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Anteris Technologies Global during the fourth quarter valued at about $33,000. Corebridge Financial Inc. purchased a new stake in Anteris Technologies Global during the first quarter valued at about $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Anteris Technologies Global during the first quarter valued at about $32,000. Deutsche Bank AG purchased a new stake in Anteris Technologies Global during the first quarter valued at about $59,000. Finally, Nuveen LLC purchased a new stake in Anteris Technologies Global during the first quarter valued at about $71,000.
Anteris Technologies Global Company Profile
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
Featured Stories
- Five stocks we like better than Anteris Technologies Global
- Which Wall Street Analysts are the Most Accurate?
- Ignore the Noise—Samsara Stock Is Still a Strong Buy
- How to Profit From Value Investing
- 3 Stocks Set to Double—And There’s Still Time to Buy
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Analysts Can’t Get Enough of These Little-Known Biopharma Stocks
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.